Thermo Fisher Scientific joins Quest Diagnostics to extend access to peanut allergy tests

Aug. 23, 2013

Thermo Fisher Scientific, Inc., has announced that its Thermo Scientific ImmunoCAP Peanut Component Tests are now available through Quest Diagnostics. Quest is broadly offering diagnostic services based on the ImmunoCAP tests to physicians, significantly broadening patient access. Under a non-exclusive agreement, the two companies will also co-market ImmunoCAP test services provided by Quest Diagnostics’ clinical laboratories.

Unlike skin scratch testing, the ImmunoCAP Peanut Component tests measure a patient’s Immunoglobulin E, or IgE, sensitization to five important individual peanut proteins, called allergen components. Some of these components are known to be responsible for severe allergic reactions in sensitized patients. Physicians may use this information to identify patients who have a good chance of passing an oral food challenge and to develop personalized treatment plans tailored to a patient’s individual risk.

Peanuts and tree nuts are the most common cause of fatal and near-fatal allergic reactions to food in the United States. A Quest Diagnostics Health Trends study published in 2011 found that peanuts were the most common source of food allergen sensitization in children ages six to 18 years of age.

While some peanut sensitized patients may react to components in the peanut that can cause severe and potentially life-threatening reactions, other patients may react only to components that usually cause only mild localized reactions. Results from peanut component testing can help to stratify a patient’s risk. Learn more about ImmunoCap Peanut Component Tests from Thermo Scientific.

Photo 115879330 © Karenr | Dreamstime.com
Photo 124723736 © Steveheap | Dreamstime.com
Photo 129549884 © Katarzyna Bialasiewicz | Dreamstime.com
Photo 159136554 © Alberto Masnovo | Dreamstime.com